Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 100 of 727

1.

[A complex chromosome translocation with male infertility of karyotype analysis and literature review].

Wu GJ, Ma S, Zheng LW, Xu Y, Meng FH, Dai XW.

Beijing Da Xue Xue Bao Yi Xue Ban. 2018 Aug 18;50(4):729-731. Review. Chinese.

2.

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis MC, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke AM, Burandt E, Steurer S, Schlomm T, Simon R.

Genes Chromosomes Cancer. 2018 Oct;57(10):504-512. doi: 10.1002/gcc.22645. Epub 2018 Aug 20.

PMID:
29923647
3.

Protocols for the Study of Taxanes Chemosensitivity in Prostate Cancer.

Luz Flores M, Sáez C.

Methods Mol Biol. 2018;1786:153-173. doi: 10.1007/978-1-4939-7845-8_9.

PMID:
29786792
4.

Biomarkers in prostate cancer - Current clinical utility and future perspectives.

Kretschmer A, Tilki D.

Crit Rev Oncol Hematol. 2017 Dec;120:180-193. doi: 10.1016/j.critrevonc.2017.11.007. Epub 2017 Nov 13. Review.

PMID:
29198331
5.

Quantification of large scale DNA organization for predicting prostate cancer recurrence.

MacAulay C, Keyes M, Hayes M, Lo A, Wang G, Guillaud M, Gleave M, Fazli L, Korbelik J, Collins C, Keyes S, Palcic B.

Cytometry A. 2017 Dec;91(12):1164-1174. doi: 10.1002/cyto.a.23287. Epub 2017 Nov 30.

6.

Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome.

Kaszuba MC, Pulido JS, Folpe AL, Pichurin PN, Goodenberger ML, Spinner RJ.

World Neurosurg. 2018 Jan;109:362-364. doi: 10.1016/j.wneu.2017.10.064. Epub 2017 Oct 20.

PMID:
29061454
7.

[Properties of cancer cell DNA affects the prognosis].

Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE.

Tidsskr Nor Laegeforen. 2017 Oct 16;137(19). doi: 10.4045/tidsskr.16.0966. Print 2017 Oct 17. Review. Norwegian.

8.

Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin.

Bhindi B, Carlson RE, Mason RJ, Schulte PJ, Gettman MT, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Leibovich BC, Karnes RJ.

Urology. 2017 Nov;109:145-152. doi: 10.1016/j.urology.2017.06.054. Epub 2017 Aug 18.

PMID:
28823636
9.

Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.

Alexandrov PN, Percy ME, Lukiw WJ.

Cell Mol Neurobiol. 2018 Apr;38(3):769-774. doi: 10.1007/s10571-017-0514-0. Epub 2017 Jul 7.

10.

Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.

Zekri A, Mesbahi Y, Ghanizadeh-Vesali S, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH.

Anticancer Drugs. 2017 Sep;28(8):841-851. doi: 10.1097/CAD.0000000000000523.

PMID:
28639950
11.

Tumour heterogeneity poses a significant challenge to cancer biomarker research.

Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjær M, Kleppe A, Hveem TS, Carlsen B, Gill S, Löffeler S, Haug ES, Wæhre H, Sooriakumaran P, Danielsen HE.

Br J Cancer. 2017 Jul 25;117(3):367-375. doi: 10.1038/bjc.2017.171. Epub 2017 Jun 15.

12.

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.

Mittal K, Donthamsetty S, Kaur R, Yang C, Gupta MV, Reid MD, Choi DH, Rida PCG, Aneja R.

Br J Cancer. 2017 Apr 25;116(9):1186-1194. doi: 10.1038/bjc.2017.78. Epub 2017 Mar 23.

13.

Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians.

Shiina M, Hashimoto Y, Kato T, Yamamura S, Tanaka Y, Majid S, Saini S, Varahram S, Kulkarni P, Dasgupta P, Mitsui Y, Sumida M, Tabatabai L, Deng G, Kumar D, Dahiya R.

Oncotarget. 2017 Jan 31;8(5):8356-8368. doi: 10.18632/oncotarget.14198.

14.

MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.

Bucay N, Sekhon K, Yang T, Majid S, Shahryari V, Hsieh C, Mitsui Y, Deng G, Tabatabai ZL, Yamamura S, Calin GA, Dahiya R, Tanaka Y, Saini S.

Oncogene. 2017 May 11;36(19):2667-2679. doi: 10.1038/onc.2016.419. Epub 2016 Nov 28.

15.

Deletion of 8p is an independent prognostic parameter in prostate cancer.

Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz TS, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, Simon R.

Oncotarget. 2017 Jan 3;8(1):379-392. doi: 10.18632/oncotarget.13425.

16.

Deletion of 18q is a strong and independent prognostic feature in prostate cancer.

Kluth M, Graunke M, Möller-Koop C, Hube-Magg C, Minner S, Michl U, Graefen M, Huland H, Pompe R, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Büscheck F, Clauditz T, Wilczak W, Sauter G, Schlomm T, Simon R.

Oncotarget. 2016 Dec 27;7(52):86339-86349. doi: 10.18632/oncotarget.13404.

17.

Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer.

Bucay N, Sekhon K, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Greene K, Tanaka Y, Dahiya R, Deng G, Saini S.

Oncotarget. 2016 Oct 25;7(43):70388-70403. doi: 10.18632/oncotarget.11865.

18.

NKAIN2 functions as a novel tumor suppressor in prostate cancer.

Mao X, Luo F, Boyd LK, Zhou B, Zhang Y, Stankiewicz E, Marzec J, Vasiljevic N, Yu Y, Feng N, Xu J, Lorincz A, Jiang Y, Chelala C, Ren G, Berney DM, Zhao SC, Lu YJ.

Oncotarget. 2016 Sep 27;7(39):63793-63803. doi: 10.18632/oncotarget.11690.

19.

Expression of circadian clock genes and proteins in urothelial cancer is related to cancer-associated genes.

Litlekalsoy J, Rostad K, Kalland KH, Hostmark JG, Laerum OD.

BMC Cancer. 2016 Jul 27;16:549. doi: 10.1186/s12885-016-2580-y.

20.

Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S.

Prostate. 2016 Sep;76(12):1067-77. doi: 10.1002/pros.23190. Epub 2016 Jun 8.

PMID:
27271795
21.

Chromatin changes predict recurrence after radical prostatectomy.

Hveem TS, Kleppe A, Vlatkovic L, Ersvær E, Wæhre H, Nielsen B, Kjær MA, Pradhan M, Syvertsen RA, Nesheim JA, Liestøl K, Albregtsen F, Danielsen HE.

Br J Cancer. 2016 May 24;114(11):1243-50. doi: 10.1038/bjc.2016.96. Epub 2016 Apr 28.

22.

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM.

Mod Pathol. 2016 Jul;29(7):764-71. doi: 10.1038/modpathol.2016.63. Epub 2016 Apr 15.

23.

Mosaic loss of chromosome Y is associated with common variation near TCL1A.

Zhou W, Machiela MJ, Freedman ND, Rothman N, Malats N, Dagnall C, Caporaso N, Teras LT, Gaudet MM, Gapstur SM, Stevens VL, Jacobs KB, Sampson J, Albanes D, Weinstein S, Virtamo J, Berndt S, Hoover RN, Black A, Silverman D, Figueroa J, Garcia-Closas M, Real FX, Earl J, Marenne G, Rodriguez-Santiago B, Karagas M, Johnson A, Schwenn M, Wu X, Gu J, Ye Y, Hutchinson A, Tucker M, Perez-Jurado LA, Dean M, Yeager M, Chanock SJ.

Nat Genet. 2016 May;48(5):563-8. doi: 10.1038/ng.3545. Epub 2016 Apr 11.

24.

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer.

Lennartz M, Minner S, Brasch S, Wittmann H, Paterna L, Angermeier K, Öztürk E, Shihada R, Ruge M, Kluth M, Koop C, Wilczak W, Krech T, Lebok P, Wittmer C, Heinzer H, Steuber T, Adam M, Huland H, Graefen M, Haese A, Simon R, Sauter G, Schlomm T.

Clin Cancer Res. 2016 Jun 1;22(11):2802-11. doi: 10.1158/1078-0432.CCR-15-0635. Epub 2016 Jan 26.

25.

Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients.

Noveski P, Madjunkova S, Sukarova Stefanovska E, Matevska Geshkovska N, Kuzmanovska M, Dimovski A, Plaseska-Karanfilska D.

PLoS One. 2016 Jan 8;11(1):e0146264. doi: 10.1371/journal.pone.0146264. eCollection 2016.

26.
27.

Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Danielsen HE, Pradhan M, Novelli M.

Nat Rev Clin Oncol. 2016 May;13(5):291-304. doi: 10.1038/nrclinonc.2015.208. Epub 2015 Nov 24. Review.

PMID:
26598944
28.

[Objective DNA malignancy grading as adjunct to the histological Gleason score: Frankfurt consensus].

Böcking A, Biesterfeld S, Dietz J, Haroske G, Kriegsmann J, Motherby H, Falk S.

Pathologe. 2015 Sep;36(5):498-502. doi: 10.1007/s00292-015-0074-3. German. No abstract available.

PMID:
26307157
29.

Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2015 Sep 29;6(29):27966-79. doi: 10.18632/oncotarget.4626. Erratum in: Oncotarget. 2017 Jan 10;8(2):3761.

30.

Chromosome Condensation 1-Like (Chc1L) Is a Novel Tumor Suppressor Involved in Development of Histiocyte-Rich Neoplasms.

Spillane DR, Wang DY, Newbigging S, Wang Y, Shi CX, Cho HR, Shimizu H, Gramolini A, Liu M, Wen XY.

PLoS One. 2015 Aug 20;10(8):e0135755. doi: 10.1371/journal.pone.0135755. eCollection 2015.

31.
32.

Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.

Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Nickels JT Jr, Rice LM.

Tumour Biol. 2015 Aug;36(8):6067-74. doi: 10.1007/s13277-015-3284-7. Epub 2015 Mar 4.

PMID:
25736928
33.

Genetic and epigenetic stability of human spermatogonial stem cells during long-term culture.

Nickkholgh B, Mizrak SC, van Daalen SK, Korver CM, Sadri-Ardekani H, Repping S, van Pelt AM.

Fertil Steril. 2014 Dec;102(6):1700-7.e1. doi: 10.1016/j.fertnstert.2014.08.022. Epub 2014 Sep 23.

PMID:
25256932
34.

Tumor clone dynamics in lethal prostate cancer.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G.

Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448.

35.

Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.

El-Mokadem I, Fitzpatrick J, Bondad J, Rauchhaus P, Cunningham J, Pratt N, Fleming S, Nabi G.

Br J Cancer. 2014 Sep 23;111(7):1381-90. doi: 10.1038/bjc.2014.420. Epub 2014 Aug 19.

36.

Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.

Heselmeyer-Haddad KM, Berroa Garcia LY, Bradley A, Hernandez L, Hu Y, Habermann JK, Dumke C, Thorns C, Perner S, Pestova E, Burke C, Chowdhury SA, Schwartz R, Schäffer AA, Paris PL, Ried T.

Am J Pathol. 2014 Oct;184(10):2671-86. doi: 10.1016/j.ajpath.2014.06.030. Epub 2014 Aug 14.

37.

KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.

Zazzeroni F, Nicosia D, Tessitore A, Gallo R, Verzella D, Fischietti M, Vecchiotti D, Ventura L, Capece D, Gulino A, Alesse E.

Biomed Res Int. 2014;2014:380398. doi: 10.1155/2014/380398. Epub 2014 Jun 19.

38.

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.

Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK.

Cancer Med. 2014 Oct;3(5):1322-35. doi: 10.1002/cam4.289. Epub 2014 Jul 3.

39.

Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.

Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ.

Mayo Clin Proc. 2014 Mar;89(3):308-18. doi: 10.1016/j.mayocp.2013.12.001. Epub 2014 Jan 31.

PMID:
24486077
40.

Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology.

Hong MK, Sapre N, Phal PM, Macintyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM, Hovens CM.

Clin Exp Metastasis. 2014 Feb;31(2):159-67. doi: 10.1007/s10585-013-9617-2. Epub 2013 Oct 2.

PMID:
24085599
41.

Validation of copy number variants associated with prostate cancer risk and prognosis.

Blackburn A, Wilson D, Gelfond J, Yao L, Hernandez J, Thompson IM, Leach RJ, Lehman DM.

Urol Oncol. 2014 Jan;32(1):44.e15-44.e20. doi: 10.1016/j.urolonc.2013.06.004. Epub 2013 Sep 17.

42.

Overexpression of nuclear distribution protein (hNUDC) causes pro-apoptosis and differentiation in Dami megakaryocytes.

Xiao Y, Zheng Y, Tan P, Xu P, Zhang Q.

Cell Prolif. 2013 Oct;46(5):576-85. doi: 10.1111/cpr.12055. Epub 2013 Sep 7.

PMID:
24010816
43.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.

44.

Flow cytometric characterization of tumor subpopulations in three sublines of the Dunning R3327 rat prostate tumor model.

Glowa C, Peschke P, Karger CP, Hahn EW, Huber PE, Debus J, Ehemann V.

Prostate. 2013 Nov;73(15):1710-20. doi: 10.1002/pros.22710. Epub 2013 Jul 12.

PMID:
23853045
45.

Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells.

Tolba MF, Esmat A, Al-Abd AM, Azab SS, Khalifa AE, Mosli HA, Abdel-Rahman SZ, Abdel-Naim AB.

IUBMB Life. 2013 Aug;65(8):716-29. doi: 10.1002/iub.1188. Epub 2013 Jul 11.

46.

miR-146b-5p inhibits glioma migration and invasion by targeting MMP16.

Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S, Wang Q, Yan Y, Kang C, Jin S, An T, Shi C, Xu J, Wei C, Liu J, Sun J, Wen Y, Zhao S, Kong Y.

Cancer Lett. 2013 Oct 10;339(2):260-9. doi: 10.1016/j.canlet.2013.06.018. Epub 2013 Jun 22.

PMID:
23796692
47.

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.

Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H.

J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223.

PMID:
23794398
48.

DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.

Keyes M, Macaulay C, Hayes M, Korbelik J, Morris WJ, Palcic B.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):829-34. doi: 10.1016/j.ijrobp.2013.04.011. Epub 2013 May 18.

PMID:
23688814
49.

Landscape of chromosome number changes in prostate cancer progression.

Braun M, Stomper J, Kirsten R, Shaikhibrahim Z, Vogel W, Böhm D, Wernert N, Kristiansen G, Perner S.

World J Urol. 2013 Dec;31(6):1489-95. doi: 10.1007/s00345-013-1051-1. Epub 2013 Mar 20.

PMID:
23512229
50.

Clonal evolution and therapeutic resistance in solid tumors.

Barrett MT, Lenkiewicz E, Evers L, Holley T, Ruiz C, Bubendorf L, Sekulic A, Ramanathan RK, Von Hoff DD.

Front Pharmacol. 2013 Jan 28;4:2. doi: 10.3389/fphar.2013.00002. eCollection 2013.

51.

Asynchronous DNA replication and aneuploidy in lymphocytes of hepatocellular carcinoma patients.

Hanna MO, Zayed NA, Darwish H, Girgis SI.

Cancer Genet. 2012 Dec;205(12):636-43. doi: 10.1016/j.cancergen.2012.10.006. Epub 2012 Nov 23.

PMID:
23182962
52.

Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.

Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, Yu-Lee LY.

Oncogene. 2013 Jun 13;32(24):2973-83. doi: 10.1038/onc.2012.309. Epub 2012 Aug 13.

53.

Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls.

Lee F, Badalament RA, Hu C, Bousho I, Tsodikov A.

J Cancer. 2012;3:122-8. doi: 10.7150/jca.4123. Epub 2012 Mar 7.

54.

Tissue biomarkers for prostate cancer radiation therapy.

Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL.

Curr Mol Med. 2012 Jul 1;12(6):772-87. Review.

55.

Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, Bertino JR, Lubin M, Wang Y.

Mol Cancer Ther. 2012 Mar;11(3):775-83. doi: 10.1158/1535-7163.MCT-11-0826. Epub 2012 Jan 17.

56.

Acute lymphoblastic leukemia in a patient with constitutional chromosome 1pter-p36.31 duplication and 1q43-qter deletion.

Khan S, Toews H, Wang JC, Arredondo J, Provias J, Göhring G, Barr RD.

J Pediatr Hematol Oncol. 2012 Apr;34(3):217-21. doi: 10.1097/MPH.0b013e31823321e5.

PMID:
22217494
57.

Gene amplification and overexpression of Aurora-C in breast and prostate cancer cell lines.

Zekri A, Lesan V, Ghaffari SH, Tabrizi MH, Modarressi MH.

Oncol Res. 2012;20(5-6):241-50.

PMID:
23581231
58.

[Chromosomal rearrangements and fusion genes in carcinoma].

Massard C, Auger N, Lacroix L, Bénard J.

Bull Cancer. 2011 Dec;98(12):1395-401. doi: 10.1684/bdc.2011.1498. Review. French.

59.

ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.

Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.

PLoS One. 2011;6(11):e28162. doi: 10.1371/journal.pone.0028162. Epub 2011 Nov 30.

60.

Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo.

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H, Kallioniemi O, Ivaska J.

Oncogene. 2012 Aug 2;31(31):3597-606. doi: 10.1038/onc.2011.527. Epub 2011 Nov 28.

61.

Efficient cryopreservation of testicular tissue: effect of age, sample state, and concentration of cryoprotectant.

Unni S, Kasiviswanathan S, D'Souza S, Khavale S, Mukherjee S, Patwardhan S, Bhartiya D.

Fertil Steril. 2012 Jan;97(1):200-8.e1. doi: 10.1016/j.fertnstert.2011.10.018. Epub 2011 Nov 17.

PMID:
22100171
62.

[Molecular pathology of multifocal prostate cancer and its clinical application].

Cheng L, Teng XD, Zhou J.

Zhonghua Bing Li Xue Za Zhi. 2011 Jul;40(7):436-9. Chinese. No abstract available.

PMID:
22088367
63.

Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age.

Stahl PR, Kilgué A, Tennstedt P, Minner S, Krohn A, Simon R, Krause GV, Izbicki J, Graefen M, Sauter G, Schlomm T, Wilczak W.

Prostate. 2012 Jun 1;72(8):898-903. doi: 10.1002/pros.21492. Epub 2011 Sep 28.

PMID:
21956681
64.

Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.

Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi JP, Smit F, Verhaegh G, Schalken J, Perälä M, Iljin K, Kallioniemi O.

Prostate. 2012 May 15;72(7):789-802. doi: 10.1002/pros.21487. Epub 2011 Sep 14.

PMID:
21919029
65.

SEPT9_i1 and genomic instability: mechanistic insights and relevance to tumorigenesis.

Peterson EA, Stanbery L, Li C, Kocak H, Makarova O, Petty EM.

Genes Chromosomes Cancer. 2011 Nov;50(11):940-9. doi: 10.1002/gcc.20916. Epub 2011 Aug 24.

66.

Tumorigenic polyploid cells contain elevated ROS and ARE selectively targeted by antioxidant treatment.

Roh M, van der Meer R, Abdulkadir SA.

J Cell Physiol. 2012 Feb;227(2):801-12. doi: 10.1002/jcp.22793.

67.

The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL.

Jeong NY, Yoon YG, Rho JH, Lee JS, Lee SY, Yoo KS, Song S, Suh H, Choi YH, Yoo YH.

Int J Oncol. 2011 Jun;38(6):1597-604. doi: 10.3892/ijo.2011.979. Epub 2011 Mar 17.

PMID:
21424121
68.

Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3β signaling, and its knockdown results in deregulated G2/M transition in prostate cells.

Varisli L, Gonen-Korkmaz C, Debelec-Butuner B, Erbaykent-Tepedelen B, Muhammed HS, Bogurcu N, Saatcioglu F, Korkmaz KS.

DNA Cell Biol. 2011 Jun;30(6):419-29. doi: 10.1089/dna.2010.1128. Epub 2011 Feb 16.

PMID:
21323578
69.

Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

Ong CA, Lao-Sirieix P, Fitzgerald RC.

World J Gastroenterol. 2010 Dec 7;16(45):5669-81. Review.

70.

Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer.

Toma MI, Friedrich K, Meyer W, Fröhner M, Schneider S, Wirth M, Baretton GB.

Anal Quant Cytol Histol. 2010 Feb;32(1):1-10.

PMID:
20701082
71.

Replication timing aberrations and aneuploidy in peripheral blood lymphocytes of breast cancer patients.

Grinberg-Rashi H, Cytron S, Gelman-Kohan Z, Litmanovitch T, Avivi L.

Neoplasia. 2010 Aug;12(8):668-74.

72.

p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS.

Mol Cancer Res. 2010 Aug;8(8):1126-41. doi: 10.1158/1541-7786.MCR-10-0174. Epub 2010 Jul 20.

73.

[Prostate biopsies endothelin-1 expression: pt3a stage prognostic factor?].

Perez T, Menard J, Joseph K, Birembaut P, Staerman F.

Prog Urol. 2010 May;20(5):364-8. doi: 10.1016/j.purol.2009.12.005. Epub 2010 Feb 20. French.

PMID:
20471581
74.

NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells.

Kim BK, Kim DM, Chung KS, Park SK, Choi SJ, Song A, Lee K, Lee CW, Song KB, Han G, Simon J, Kim HM, Won M.

Invest New Drugs. 2011 Oct;29(5):853-60. doi: 10.1007/s10637-010-9433-3. Epub 2010 Apr 30.

PMID:
20432054
75.

Characterization of prostate cancer in needle biopsy by cathepsin B, cell proliferation and DNA ploidy.

Qian J, Bostwick DG, Iczkowski KA, Betre K, Wilson MJ, LE C, Sinha AA.

Anticancer Res. 2010 Mar;30(3):719-25.

PMID:
20392989
76.

Spermatogenesis in Klinefelter syndrome.

Selice R, Di Mambro A, Garolla A, Ficarra V, Iafrate M, Ferlin A, Foresta C.

J Endocrinol Invest. 2010 Dec;33(11):789-93. doi: 10.3275/6935. Epub 2010 Mar 22.

PMID:
20332707
77.

A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.

Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V.

PLoS One. 2010 Mar 11;5(3):e9657. doi: 10.1371/journal.pone.0009657.

78.

Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas.

Bantis A, Patsouris E, Gonidi M, Kavantzas N, Tsipis A, Athanassiadou AM, Aggelonidou E, Athanassiadou P.

Tumori. 2009 Nov-Dec;95(6):744-52.

PMID:
20210240
79.

Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?

Tollefson M, Magera J, Sebo T, Cohen J, Drauch A, Maier J, Frank I.

BJU Int. 2010 Aug;106(4):484-8. doi: 10.1111/j.1464-410X.2010.09185.x. Epub 2010 Mar 1.

80.

Deletion of hepatocyte nuclear factor-1-beta in an infant with prune belly syndrome.

Haeri S, Devers PL, Kaiser-Rogers KA, Moylan VJ Jr, Torchia BS, Horton AL, Wolfe HM, Aylsworth AS.

Am J Perinatol. 2010 Aug;27(7):559-63. doi: 10.1055/s-0030-1248943. Epub 2010 Feb 19.

PMID:
20175044
81.

Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy.

Wasylyk C, Zambrano A, Zhao C, Brants J, Abecassis J, Schalken JA, Rogatsch H, Schaefer G, Pycha A, Klocker H, Wasylyk B.

Int J Cancer. 2010 Dec 1;127(11):2542-53. doi: 10.1002/ijc.25261.

82.

Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.

Jain D, Patel N, Shelton M, Basu A, Roque R, Siede W.

Cancer Chemother Pharmacol. 2010 Oct;66(5):945-52. doi: 10.1007/s00280-010-1246-8. Epub 2010 Jan 26.

PMID:
20101404
83.

RAB6C is a retrogene that encodes a centrosomal protein involved in cell cycle progression.

Young J, Ménétrey J, Goud B.

J Mol Biol. 2010 Mar 19;397(1):69-88. doi: 10.1016/j.jmb.2010.01.009. Epub 2010 Jan 11.

PMID:
20064528
84.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.

El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T.

Clin Cancer Res. 2010 Jan 1;16(1):56-64. doi: 10.1158/1078-0432.CCR-09-1423. Epub 2009 Dec 22.

85.

High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.

Braun K, Ehemann V, Wiessler M, Pipkorn R, Didinger B, Mueller G, Waldeck W.

Int J Med Sci. 2009 Nov 18;6(6):338-47.

86.

Large scale genomic instability as an additive prognostic marker in early prostate cancer.

Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, Giercksky KE, Danielsen HE.

Cell Oncol. 2009;31(4):251-9. doi: 10.3233/CLO-2009-0463.

87.

Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.

Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, Demichelis F, Freeman MR.

Cancer Res. 2009 Jul 1;69(13):5601-9. doi: 10.1158/0008-5472.CAN-08-3860. Epub 2009 Jun 23.

88.

Predictive models in external beam radiotherapy for clinically localized prostate cancer.

Roach M 3rd, Waldman F, Pollack A.

Cancer. 2009 Jul 1;115(13 Suppl):3112-20. doi: 10.1002/cncr.24348. Review.

89.

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA.

Cancer Res. 2009 Apr 1;69(7):2734-8. doi: 10.1158/0008-5472.CAN-08-4926. Epub 2009 Mar 17.

90.

Lymphoepithelioma-like carcinoma of the prostate.

Lopez-Beltran A, Cheng L, Prieto R, Blanca A, Montironi R.

Hum Pathol. 2009 Jul;40(7):982-7. doi: 10.1016/j.humpath.2008.12.008. Epub 2009 Mar 9.

PMID:
19269013
91.

DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.

Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW.

Urology. 2009 May;73(5):1092-7. doi: 10.1016/j.urology.2008.09.060. Epub 2009 Feb 3.

92.

Role and regulation of autophagy in cancer.

Chen N, Karantza-Wadsworth V.

Biochim Biophys Acta. 2009 Sep;1793(9):1516-23. doi: 10.1016/j.bbamcr.2008.12.013. Epub 2009 Jan 2. Review.

93.

Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.

Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim ST, Zheng SL, Xu J, Isaacs WB, Chang BL.

Prostate. 2009 Feb 15;69(3):327-35. doi: 10.1002/pros.20882.

94.

Genetic and epigenetic inactivation of LPL gene in human prostate cancer.

Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, Xu J, Isaacs WB, Chang BL.

Int J Cancer. 2009 Feb 1;124(3):734-8. doi: 10.1002/ijc.23972.

95.

A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells.

Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA.

PLoS One. 2008 Jul 2;3(7):e2572. doi: 10.1371/journal.pone.0002572.

96.

Deletion at chromosome arms 6q16-22 and 10q22.3-23.1 associated with initiation of prostate cancer.

Lu T, Hano H.

Prostate Cancer Prostatic Dis. 2008;11(4):357-61. doi: 10.1038/pcan.2008.4. Epub 2008 Jan 29.

PMID:
18227855
97.

Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast.

Green AR, Krivinskas S, Young P, Rakha EA, Paish EC, Powe DG, Ellis IO.

Breast Cancer Res Treat. 2009 Jan;113(1):59-66. doi: 10.1007/s10549-008-9905-8. Epub 2008 Jan 23.

PMID:
18213475
98.

Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives.

Tseng CH, Chen YL, Lu PJ, Yang CN, Tzeng CC.

Bioorg Med Chem. 2008 Mar 15;16(6):3153-62. doi: 10.1016/j.bmc.2007.12.028. Epub 2007 Dec 23.

PMID:
18180162
99.

The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells.

Hsieh TC, Traganos F, Darzynkiewicz Z, Wu JM.

Int J Oncol. 2007 Dec;31(6):1293-300.

100.

Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.

Sørensen KD, Borre M, Ørntoft TF, Dyrskjøt L, Tørring N.

Int J Cancer. 2008 Feb 1;122(3):509-19.

Supplemental Content

Loading ...
Support Center